Table 2 PLD use beyond first line treatment
From: A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
Patients (%) | |
|---|---|
II line treatment | 55 |
  ○ Pld | 22 (40% ) |
  ○ other therapy | 33 (60% ) |
Among all treatment lines | |
  ○ Pld | 30 (54%) |
  ○ other therapy | 25 (46%) |